Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

In one of its first for­ays in­to ra­dio­phar­ma­ceu­ti­cals, Roche’s Genen­tech has lined up a dis­cov­ery and de­vel­op­ment pact with the pep­tide spe­cial­ists at Pep­tiDream. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.